GSK plc American Depositary Shares (Each representing two Ordinary Share (GSK) Covered Calls

GSK plc is a global biopharmaceutical leader focused on uniting science, technology, and talent to get ahead of disease together. By 2026, the company has completed its transition under new CEO Luke Miels, prioritizing high-growth specialty medicines and vaccines. GSK is currently a dominant force in the respiratory and HIV markets, leveraging its ViiV Healthcare majority stake to pioneer long-acting injectables while rapidly scaling its oncology portfolio through ADC and IO therapies.

You can sell covered calls on GSK plc American Depositary Shares (Each representing two Ordinary Share to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GSK (prices last updated Tue 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

GSK operates a streamlined "New GSK" model focused on four therapeutic areas: Infectious Diseases, HIV, Oncology, and Respiratory/Immunology. In 2026, the company achieved record performance in its specialty portfolio. Their primary segments include:

1. Vaccines: The global leader by revenue, anchored by Shingrix (shingles) and the 2025/2026 expansion of Arexvy (RSV) into broader adult populations. This segment remains a foundational cash generator.
2. HIV (ViiV Healthcare): A market-leading unit focused on the "Long-Acting Revolution." Key products include Cabenuva and Apretude. In 2026, GSK is defending its share against Gilead with 3rd-generation integrase inhibitors that offer extended dosing windows.
3. Specialty Medicines: Featuring Nucala for severe asthma and COPD, and the fast-growing oncology franchise led by Jemperli (endometrial cancer) and Ojjaara (myelofibrosis).
4. General Medicines: A portfolio of established primary care brands, including Trelegy and Ventolin, now being optimized through AI-driven manufacturing and a focus on "carbon-neutral" inhaler technology.

Competitive Landscape

GSK competes in an elite tier of global pharmaceutical firms. Its most intense rivalry remains with Gilead Sciences in the HIV space, where the two are locked in a battle over long-acting injectable dominance. In the vaccines market, it faces Pfizer and Sanofi. Within oncology and respiratory, it contends with AstraZeneca and Merck. Despite the spin-off of Haleon, GSK still competes indirectly for investor "yield" capital against diversified peers like AbbVie and Bristol Myers Squibb.

Strategic Outlook and Innovation

The 2026 strategic roadmap for GSK is defined by "The Miels Reset." Under new CEO Luke Miels, the company is targeting 7-9% operating profit growth through 2026 by accelerating R&D and pursuing "tuck-in" acquisitions in the $2 billion to $4 billion range, such as the recent Rapt Therapeutics buyout. Innovation is centered on AI-Enabled Drug Discovery; GSK is utilizing its AI hub in London to compress clinical timelines for its late-stage pipeline, specifically for its next-gen pneumococcal vaccine. A major 2026 milestone is the launch of Xzenta for severe allergies, which utilizes a novel IgE-targeting mechanism. Despite the "patent cliff" for dolutegravir approaching in 2028, GSK has successfully pivoted over 35% of its HIV revenue to long-acting assets. With a dividend payout ratio targeted at 40-50%, GSK remains a favorite for income-oriented investors seeking defensive exposure to the "Age of Immunology."

Want more examples? GSIT Covered Calls | GSL Covered Calls